



SEQUENCE LISTING

<110> Cooper, Denise R.
Patel, Niketa A.

<120> Introduction of a Glucose-Regulated Instability Element
Via Alternative Exon Inclusion of PKCBII mRNA in
Vascular Smooth Muscle Cells

<130> 114205.1200

<140> 09/435,471

<141> 1999-11-08

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (2)..(6)

<223> Xaa at amino acid residues 2-6 is any amino acid
residue

<400> 1

Cys Xaa Xaa Xaa Xaa Xaa Arg

1

5

<210> 2

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(10)

<223> Xaa at amino acid residue 1 is Ile or Val, Xaa at
amino acid residue 10 is Ser or Thr, Xaa at amino
acid residues 4 and 7 is any amino acid residue

<400> 2

Xaa His Cys Xaa Ala Gly Xaa Gly Arg Xaa Gly

RECEIVED

JUL 10 2001

TECH CENTER 1600/2900

1 5 10

<210> 3
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (2)..(7)
<223> Xaa at residue positions 3-4 and 6-7 is any amino
acid residue

<400> 3
His Cys Xaa Xaa Gly Xaa Xaa Arg Xaa
1 5

<210> 4
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 4
cgtatatgcg gccgcgttgt gggcctgaag ggg

33

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 5
gcattctagt cgacaagagt ttgtcagtgg gag

33

<210> 6
<211> 22
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 6

gcattcthtc cagtgaggag aa

22

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 7

aaccagcacg ttgccagga g

21

<210> 8

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 8

cgtatatgcg gccgcgttgt gggcctgaag ggg

33

<210> 9

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 9

gcattctagt cgacaagagt ttgtcagtgg gag

33

<210> 10
 <211> 351
 <212> DNA
 <213> Human PKC BetaII

<400> 10
 ttttaaacca aaagcttttt gggcgaaacg ctgaaacttc gaccggtttt tcacccgcca 60
 tccaccagtc ctaacacctc cgaccaggaa gtcatcagga atattgacca atcagaattc 120
 gaaggatttc ctttggttaac tctgaatttt taaaacccga agtcaagagc tagtagatct 180
 gtagacctcc gtccttcatt tctgtcattc aagctcacag ctatcatgag agacaagcga 240
 gacacctcca acttcgacaa aagttcacca ggcagcctgt ggaactgact cccactgaca 300
 aactctgtcg actagaatgc cctgaattct gcagatatcc atcacactgc g 351

<210> 11
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: nucleic acid
 construct

B1
 <220>
 <223> metabolite responsive instability element

<400> 11
 taactctgaa tttttaaaac ccgaagtcaa gagctagta 39

<210> 12
 <211> 300
 <212> RNA
 <213> Human PCK Beta II

<220>
 <221> mRNA
 <222> (1)..(300)

<400> 12
 uuuuaaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60
 uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120
 gaaggauuuc cuuuguaaac ucugaauuuu uaaaacccga agucaagagc uaguagauuc 180
 guagaccucc guccuucuu ucugucuuuc aagcucacag cuaucaugag agacaagcga 240
 gacaccucca acuucgacaa aaguucacca ggcagccugu ggaacugacu cccacugaca 300

<210> 13
<211> 175
<212> RNA
<213> Human PCK Beta II

<220>
<221> mRNA
<222> (1)..(175)

<400> 13
uuuuuaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60
uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaaauuc 120
gaaggauuuc cuuuguuaac ucugaauuuu uaaaacccga agucaagagc uagua 175

B1
(end)

<210> 14
<211> 137
<212> RNA
<213> Human Beta PCK II

<220>
<221> mRNA
<222> (1)..(137)

<400> 14
uuuuuaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60
uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaaauuc 120
gaaggauuuc cuuuguu 137
